Abatacept Injection for Juvenile Idiopathic Arthritis
(Limit-JIA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
Who Is on the Research Team?
Laura Schanberg, MD
Principal Investigator
Duke University
Eveline Wu, MD
Principal Investigator
University of North Carolina, Chapel Hill
Are You a Good Fit for This Trial?
This trial is for children aged 2 to 16.5 with recent-onset Juvenile Idiopathic Arthritis affecting up to 4 joints and not yet severe. They must be enrolled in the CARRA Registry, agree to birth control if applicable, and weigh over 50 kg in Canada. Exclusions include a history of psoriasis or uveitis, certain infections or treatments, other clinical study participation within 30 days, and various medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment (Part I)
Participants receive 24 weeks of abatacept plus usual care or usual care alone
Follow-up (Part I)
Participants undergo follow-up for assessment of outcomes after treatment
Treatment (Part II)
Participants receive 24 doses of abatacept plus usual care
Follow-up (Part II)
Participants undergo follow-up for assessment of outcomes after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Abatacept Injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor